StockWatch
·

SBC Medical Group Holdings Inc Q3 FY25 Results

SBCQ3 FY25 Results
Filing
MetricValue ($ M)Q2 FY25Q3 FY24
Revenue43.350.0%18.3%
Total Income43.350.0%18.3%
Expenditure27.474.6%30.0%
PBT18.5136.7%41.2%
Net Profit12.82421.1%353.0%
OPM36.63%3.06pp10.57pp
NPM29.58%23.91pp24.25pp
EPS0.12500.0%300.0%
View full financials

SBC Medical Group Holdings Reports Q3 2025 Results

04 May 2026 · 4 May, 7:08 am

Summary

SBC Medical Group Holdings Incorporated announced its financial results for the third quarter of fiscal year 2025. Total revenues were $43 million, an 18% decrease year-over-year, primarily due to a revised fee structure for clinic services. Net income attributable to SBC Medical Group was $13 million, compared to $3 million in the same period of 2024, driven by lower operating expenses. EBITDA was $17 million, a 12% increase, with an EBITDA margin of 38%.

Key Highlights

  1. 1

    Total revenues were $43 million, representing an 18% year-over-year decrease.

  2. 2

    Income from operations was $16 million, representing a 15% year-over-year increase.

  3. 3

    Net Income attributable to SBC Medical Group was $13 million, representing an 353% year-over-year increase.

  4. 4

    Earnings per share was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024.

  5. 5

    EBITDA was $17 million, representing a 12% year-over-year increase, with an EBITDA margin of 38% for the third quarter of 2025.

  6. 6

    The number of Franchise Locations was 258 as of September 30, 2025, representing an increase of 34 locations from September 30, 2024.

  7. 7

    The number of customers in the last twelve months ended September 30, 2025, was 6.5 million, representing a 14% year-over-year increase.

Management Comments

Y

Yoshiyuki Aikawa

In Q3 2025, SBC Medical’s revenue decreased by 18% year over year. This decline primarily reflects the impact of our past business restructuring initiatives, including the revision of franchise fees and the deconsolidation of certain group entities. Meanwhile, rental revenue remained solid, supported by the renewal of medical equipment, and the consolidation of AHH contributed positively to overall performance. Profitability improved significantly during the quarter. Income from operations increased by 15% year over year, net profit rose by 353%, and income from operations margin strengthened to 37%. These improvements were mainly driven by the absence of IPO-related and stock-based compensation expenses recorded in the prior year, indicating that our cost structure is normalizing toward a sustainable level. Looking ahead, we will continue to pursue sustainable growth toward 2026 by focusing on delivering high-quality solutions, advancing multi-brand initiatives in the dermatology segment, and building a stronger business foundation in overseas markets.”

Informational and educational content only. Not investment advice.